MAPT and tauopathy: However, the enormous effort put on finding ways to revert or delay the neurodegeneration symptoms associated to fibrillar tau, or to prevent the onset of tauopathies, has been so far unsuccessful, partly due to the intrinsically disordered nature of tau, which hampers drug design based on structural approaches.